Parkinson's Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abeliovich, 2000, Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system, Neuron, 25, 239, 10.1016/S0896-6273(00)80886-7
Ahn, 2002, Alpha-synuclein interacts with phospholipase D isozymes and inhibits pervanadate induced phospholipase D activation in human embryonic kidney 293 cells, J. Biol. Chem., 277, 12334, 10.1074/jbc.M110414200
Auluck, 2002, Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease, Science, 295, 865, 10.1126/science.1067389
Beckman, 1998, The free radical theory of aging matures, Physiol. Rev., 78, 547, 10.1152/physrev.1998.78.2.547
Bergman, 1990, Reversal of experimental parkinsonism by lesions of the subthalamic nucleus, Science, 249, 1436, 10.1126/science.2402638
Bernheimer, 1973, Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations, J. Neurol. Sci., 20, 415, 10.1016/0022-510X(73)90175-5
Betarbet, 2000, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat. Neurosci., 3, 1301, 10.1038/81834
Bezard, 1999, Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter, Exp. Neurol., 155, 268, 10.1006/exnr.1998.6995
Bilsland, 2002, Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons, J. Neurosci., 22, 2637, 10.1523/JNEUROSCI.22-07-02637.2002
Bjorklund, 2002, Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model, Proc. Natl. Acad. Sci. USA, 99, 2344, 10.1073/pnas.022438099
Bonifati, 2002, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science, 299, 256, 10.1126/science.1077209
Brooks, 1999, Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss, Brain Res., 823, 1, 10.1016/S0006-8993(98)01192-5
Burns, 1983, A primate model of parkinsonism, Proc. Natl. Acad. Sci. USA, 80, 4546, 10.1073/pnas.80.14.4546
Bussell, 2001, Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein, J. Biol. Chem., 276, 45996, 10.1074/jbc.M106777200
Cabin, 2002, Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein, J. Neurosci., 22, 8797, 10.1523/JNEUROSCI.22-20-08797.2002
Chan, 1991, Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain, J. Neurochem., 57, 348, 10.1111/j.1471-4159.1991.tb02134.x
Chan, 1998, Failure to find the α-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease, Neurology, 50, 513, 10.1212/WNL.50.2.513
Chung, 2001, Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1, Nat. Med., 7, 1144, 10.1038/nm1001-1144
Clarke, 1999, Apoptosis versus necrosis
Cohen, 1984, Oxy-radical toxicity in catecholamine neurons, Neurotoxicology, 5, 77
Cohen, 2000, Oxidative stress, mitochondrial respiration, and Parkinson's disease, Ann. N Y Acad. Sci., 899, 112, 10.1111/j.1749-6632.2000.tb06180.x
Cohen, 1994, Free radicals, oxidative stress, and neurodegeneration
Conway, 1998, Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease, Nat. Med., 4, 1318, 10.1038/3311
Conway, 2000, Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease, Proc. Natl. Acad. Sci. USA, 97, 571, 10.1073/pnas.97.2.571
Conway, 2001, Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct, Science, 294, 1346, 10.1126/science.1063522
Cummings, 1999, Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice, Neuron, 24, 879, 10.1016/S0896-6273(00)81035-1
Cummings, 2001, Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice, Hum. Mol. Genet., 10, 1511, 10.1093/hmg/10.14.1511
D'Amato, 1986, Selectivity of the parkinsonian neurotoxin MPTP, Science, 231, 987, 10.1126/science.3080808
Damier, 1999, The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry, Brain, 122, 1421, 10.1093/brain/122.8.1421
Damier, 1999, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease, Brain, 122, 1437, 10.1093/brain/122.8.1437
Dauer, 2002, Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP, Proc. Natl. Acad. Sci. USA, 99, 14524, 10.1073/pnas.172514599
Davey, 1996, Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria, J. Neurochem., 66, 1617, 10.1046/j.1471-4159.1996.66041617.x
Davey, 1998, Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration, J. Biol. Chem., 273, 12753, 10.1074/jbc.273.21.12753
Davidson, 1998, Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes, J. Biol. Chem., 273, 9443, 10.1074/jbc.273.16.9443
Davis, 1979, Chronic parkinsonism secondary to intravenous injection of meperidine analogs, Psychiatry Res., 1, 249, 10.1016/0165-1781(79)90006-4
Day, 1999, A mechanism of paraquat toxicity involving nitric oxide synthase, Proc. Natl. Acad. Sci. USA, 96, 12760, 10.1073/pnas.96.22.12760
Duan, 2002, p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism, Ann. Neurol., 52, 597, 10.1002/ana.10350
Duffy, 1965, Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease, J. Neuropathol. Exp. Neurol., 24, 398, 10.1097/00005072-196507000-00003
Eberhardt, 2000, Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease, J. Neurosci., 20, 9126, 10.1523/JNEUROSCI.20-24-09126.2000
Eliezer, 2001, Conformational properties of alpha-synuclein in its free and lipid-associated states, J. Mol. Biol., 307, 1061, 10.1006/jmbi.2001.4538
Fabre, 1999, Effect of MPTP on brain mitochondrial H2O2 and ATP production and on dopamine and DOPAC in the striatum, J. Physiol. Biochem., 55, 325
Farrer, 2001, alpha-Synuclein gene haplotypes are associated with Parkinson's disease, Hum. Mol. Genet., 10, 1847, 10.1093/hmg/10.17.1847
Ferrante, 1997, Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra, Brain Res., 753, 157, 10.1016/S0006-8993(97)00008-5
Forno, 1996, Neuropathology of Parkinson's disease, J. Neuropathol. Exp. Neurol., 55, 259, 10.1097/00005072-199603000-00001
Forno, 1986, Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys, Ann. Neurol., 20, 449, 10.1002/ana.410200403
Forno, 1993, Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease, Adv. Neurol., 60, 600
Gash, 1996, Functional recovery in parkinsonian monkeys treated with GDNF, Nature, 380, 252, 10.1038/380252a0
George, 1995, Characterization of a novel protein regulated during the critical period for song learning in the zebra finch, Neuron, 15, 361, 10.1016/0896-6273(95)90040-3
Ghahremani, 2002, Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of embryonic cortical neurons evoked by DNA damage, J. Biol. Chem., 277, 35586, 10.1074/jbc.M204362200
Ghee, 2000, Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex, J. Neurochem., 75, 2221, 10.1046/j.1471-4159.2000.0752221.x
Giasson, 1999, Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro, J. Biol. Chem., 274, 7619, 10.1074/jbc.274.12.7619
Giasson, 2000, Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions, Science, 290, 985, 10.1126/science.290.5493.985
Giasson, 2002, Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein, Neuron, 34, 521, 10.1016/S0896-6273(02)00682-7
Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 51, 745, 10.1136/jnnp.51.6.745
Gill, 2003, Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease, Nat. Med., 9, 589, 10.1038/nm850
Giovanni, 1991, Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice, J. Pharmacol. Exp. Ther., 257, 691
Giovanni, 1994, Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1, J. Pharmacol. Exp. Ther., 270, 1000
Giros, 1996, Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter, Nature, 379, 606, 10.1038/379606a0
Goedert, 2001, Alpha-synuclein and neurodegenerative diseases, Nat. Rev. Neurosci., 2, 492, 10.1038/35081564
Gogos, 1998, Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior, Proc. Natl. Acad. Sci. USA, 95, 9991, 10.1073/pnas.95.17.9991
Graham, 1978, Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones, Mol. Pharmacol., 14, 633
Haber, 1995, Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter, J. Comp. Neurol., 362, 400, 10.1002/cne.903620308
Hallman, 1984, Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse, Eur. J. Pharmacol., 97, 133, 10.1016/0014-2999(84)90521-1
Hartmann, 2001, Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?, J. Neurochem., 76, 1785, 10.1046/j.1471-4159.2001.00160.x
Hartmann, 2001, Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis, J. Neurosci., 21, 2247, 10.1523/JNEUROSCI.21-07-02247.2001
Hartmann, 2002, Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease, Neurobiol. Dis., 10, 28, 10.1006/nbdi.2002.0494
Hasegawa, 1997, A dual effect of 1-methyl-4-phenylpyridinium (MPP+)-analogs on the respiratory chain of bovine heart mitochondria, Arch. Biochem. Biophys., 337, 69, 10.1006/abbi.1996.9726
Hasegawa, 1990, 1-Mehtyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles, Biochem. Biophys. Res. Commun., 170, 1049, 10.1016/0006-291X(90)90498-C
Hashimoto, 1999, Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease, J. Biol. Chem., 274, 28849, 10.1074/jbc.274.41.28849
Hedrich, 2002, Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations, Neurology, 58, 1239, 10.1212/WNL.58.8.1239
Hefti, 1980, Partial lesions of the dopaminergic nigrostriatal system in rat brain, Brain Res., 195, 123, 10.1016/0006-8993(80)90871-9
Hely, 1989, The Sydney Multicentre Study of Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 52, 324, 10.1136/jnnp.52.3.324
Herkenham, 1991, Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration, Neuroscience, 40, 133, 10.1016/0306-4522(91)90180-V
Hernan, 2002, A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, Ann. Neurol., 52, 276, 10.1002/ana.10277
Herrero, 1993, Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP, Neuroscience, 56, 499, 10.1016/0306-4522(93)90349-K
Hilker, 2001, Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene, Ann. Neurol., 49, 367, 10.1002/ana.74
Hirsch, 1988, Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease, Nature, 334, 345, 10.1038/334345a0
Hisata, J. (2002). Final supplemental environmental impact statement. Lake and stream rehabilitation: rotenone use and health risks (Washington Department of Fish and Wildlife).
Hoglinger, 2003, Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats, J. Neurochem., 84, 1, 10.1046/j.1471-4159.2003.01533.x
Hornykiewicz, 1987, Biochemical pathophysiology of Parkinson's disease
Imai, 2001, An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin, Cell, 105, 891, 10.1016/S0092-8674(01)00407-X
Irwin, 1993, MPTP and aging, Adv. Neurol., 60, 197
Jackson-Lewis, 1995, Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurodegeneration, 4, 257, 10.1016/1055-8330(95)90015-2
Jackson-Lewis, 2000, Developmental cell death in dopaminergic neurons of the substantia nigra of mice, J. Comp. Neurol., 424, 476, 10.1002/1096-9861(20000828)424:3<476::AID-CNE6>3.0.CO;2-0
Javitch, 1985, Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci. USA, 82, 2173, 10.1073/pnas.82.7.2173
Javoy, 1976, Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system, Brain Res., 102, 210, 10.1016/0006-8993(76)90877-5
Jensen, 1998, Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation, J. Biol. Chem., 273, 26292, 10.1074/jbc.273.41.26292
Jensen, 1999, alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356, J. Biol. Chem., 274, 25481, 10.1074/jbc.274.36.25481
Jensen, 2000, Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments, J. Biol. Chem., 275, 21500, 10.1074/jbc.M000099200
Jeon, 1995, 6-hydroxydopamine lesion of the rat substantia nigra, Neurodegeneration, 4, 131, 10.1006/neur.1995.0016
Jiang, 1993, Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats, Brain Res., 613, 347, 10.1016/0006-8993(93)90925-D
Johnson, 1988, Accumulation of biological amines into chromaffin granules, Physiol. Rev., 68, 232, 10.1152/physrev.1988.68.1.232
Jonsson, 1980, Chemical neurotoxins as denervation tools in neurobiology, Annu. Rev. Neurosci., 3, 169, 10.1146/annurev.ne.03.030180.001125
Jonsson, 1983, Chemical lesioning techniques
Kahle, 2002, Structure/function of alpha-synuclein in health and disease, J. Neurochem., 82, 449, 10.1046/j.1471-4159.2002.01020.x
Kirik, 2002, Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system, J. Neurosci., 22, 2780, 10.1523/JNEUROSCI.22-07-02780.2002
Kitada, 1998, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392, 605, 10.1038/33416
Klaidman, 1993, Redox cycling of MPP+, Free Radic. Biol. Med., 15, 169, 10.1016/0891-5849(93)90056-Z
Kopito, 2000, Aggresomes, inclusion bodies and protein aggregation, Trends Cell Biol., 10, 524, 10.1016/S0962-8924(00)01852-3
Kordower, 2000, Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease, Science, 290, 767, 10.1126/science.290.5492.767
Kostic, 1997, Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis, Ann. Neurol., 41, 497, 10.1002/ana.410410413
Kruger, 1998, Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease, Nat. Genet., 18, 107, 10.1038/ng0298-106
Langston, 1983, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219, 979, 10.1126/science.6823561
Langston, 1999, Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure, Ann. Neurol., 46, 598, 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F
Lashuel, 2002, Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils, J. Mol. Biol., 322, 1089, 10.1016/S0022-2836(02)00735-0
Lee, 2001, Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis, FASEB J., 15, 916, 10.1096/fj.00-0334com
Lee, 2002, Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors, J. Biol. Chem., 277, 5411, 10.1074/jbc.M105326200
Lee, 2002, Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice, Proc. Natl. Acad. Sci. USA, 99, 8968, 10.1073/pnas.132197599
Lei, 2002, The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase, Mol. Cell. Biol., 22, 4929, 10.1128/MCB.22.13.4929-4942.2002
Levecque, 2001, No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease, J. Neural Transm., 108, 979, 10.1007/s007020170017
Levy, 2002, The association of incident dementia with mortality in PD, Neurology, 59, 1708, 10.1212/01.WNL.0000036610.36834.E0
Li, 2002, Age at onset in two common neurodegenerative diseases is genetically controlled, Am. J. Hum. Genet., 70, 985, 10.1086/339815
Limousin, 1998, Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease, N. Engl. J. Med., 339, 1105, 10.1056/NEJM199810153391603
Liou, 1997, Environmental risk factors and Parkinson's disease, Neurology, 48, 1583, 10.1212/WNL.48.6.1583
Liu, 1992, Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium, Proc. Natl. Acad. Sci. USA, 89, 9074, 10.1073/pnas.89.19.9074
Liu, 2002, The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility, Cell, 111, 209, 10.1016/S0092-8674(02)01012-7
Lo Bianco, 2002, alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease, Proc. Natl. Acad. Sci. USA, 99, 10813, 10.1073/pnas.152339799
Lucking, 2000, Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group, N. Engl. J. Med., 342, 1560, 10.1056/NEJM200005253422103
Luthman, 1989, Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat, Behav. Brain Res., 33, 267, 10.1016/S0166-4328(89)80121-4
Macaya, 1994, Apoptosis in substantia nigra following developmental striatal excitotoxic injury, Proc. Natl. Acad. Sci. USA, 91, 8117, 10.1073/pnas.91.17.8117
Mandavilli, 2000, DNA damage in brain mitochondria caused by aging and MPTP treatment, Brain Res., 885, 45, 10.1016/S0006-8993(00)02926-7
Mandir, 1999, Poly (ADP-ribose) polymerase activation mediates MPTP-induced parkinsonism, Proc. Natl. Acad. Sci. USA, 96, 5774, 10.1073/pnas.96.10.5774
Manning-Bog, 2002, The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice, J. Biol. Chem., 277, 1641, 10.1074/jbc.C100560200
Maraganore, 1999, Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease, Neurology, 53, 1858, 10.1212/WNL.53.8.1858
Markey, 1984, Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism, Nature, 311, 464, 10.1038/311464a0
Marsden, 1983, Neuromelanin and Parkinson's disease, J. Neural Transm. Suppl., 19, 121
Martin, 2001, Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease, JAMA, 286, 2245, 10.1001/jama.286.18.2245
Masliah, 2000, Dopaminergic loss and inclusion body formation in alpha-synuclein mice, Science, 287, 1265, 10.1126/science.287.5456.1265
Matsuoka, 2001, Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter, Neurobiol. Dis., 8, 535, 10.1006/nbdi.2001.0392
Mayer, 1986, Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport, J. Neurochem., 47, 1073, 10.1111/j.1471-4159.1986.tb00722.x
McCormack, 2002, Environmental risk factors and Parkinson's disease, Neurobiol. Dis., 10, 119, 10.1006/nbdi.2002.0507
McGeer, 1988, Rate of cell death in parkinsonism indicates active neuropathological process, Ann. Neurol., 24, 574, 10.1002/ana.410240415
Miller, 1999, Dopamine transporters and neuronal injury, Trends Pharmacol. Sci., 20, 424, 10.1016/S0165-6147(99)01379-6
Mitsumoto, 2001, DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin, Free Radic. Res., 35, 885, 10.1080/10715760100301381
Mitsumoto, 2001, Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat, Free Radic. Res., 35, 301, 10.1080/10715760100300831
Mizuno, 2001, Parkin and Parkinson's disease, Curr. Opin. Neurol., 14, 477, 10.1097/00019052-200108000-00008
Moratalla, 1992, Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci. USA, 89, 3859, 10.1073/pnas.89.9.3859
Muchowski, 2002, Protein misfolding, amyloid formation, and neurodegeneration, Neuron, 35, 9, 10.1016/S0896-6273(02)00761-4
Mundorf, 2001, Catecholamine release and uptake in the mouse prefrontal cortex, J. Neurochem., 79, 130, 10.1046/j.1471-4159.2001.00554.x
Munoz, 1997, Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients, Neurosci. Lett., 235, 57, 10.1016/S0304-3940(97)00710-6
Murphy, 2000, Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons, J. Neurosci., 20, 3214, 10.1523/JNEUROSCI.20-09-03214.2000
Muthane, 1994, Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1mice, Exp. Neurol., 126, 195, 10.1006/exnr.1994.1058
Nagatsu, 1997, Isoquinoline neurotoxins in the brain and Parkinson's disease, Neurosci. Res., 29, 99, 10.1016/S0168-0102(97)00083-7
Nicklas, 1985, Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP, Life Sci., 36, 2503, 10.1016/0024-3205(85)90146-8
Nicklas, 1987, MPTP, MPP+ and mitochondrial function, Life Sci., 40, 721, 10.1016/0024-3205(87)90299-2
Offen, 1998, Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity, Proc. Natl. Acad. Sci. USA, 95, 5789, 10.1073/pnas.95.10.5789
Ovadia, 1995, Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys, Neurobiol. Aging, 16, 931, 10.1016/0197-4580(95)02012-8
Pappolla, 1986, Lewy bodies of Parkinson's disease. Immune electron microscopic demonstration of neurofilament antigens in constituent filaments, Arch. Pathol. Lab. Med., 110, 1160
Parker, 1989, Abnormalities of the electron transport chain in idiopathic Parkinson's disease, Ann. Neurol., 26, 719, 10.1002/ana.410260606
Pendleton, 2002, Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster, J. Pharmacol. Exp. Ther., 300, 91, 10.1124/jpet.300.1.91
Petrucelli, 2002, Parkin protects against the toxicity associated with mutant alpha-synuclein, Neuron, 36, 1007, 10.1016/S0896-6273(02)01125-X
Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045
Price, 1978, Neurochemistry of Parkinson's disease, Adv. Biochem. Psychopharmacol., 19, 293
Pronin, 2000, Synucleins are a novel class of substrates for G protein-coupled receptor kinases, J. Biol. Chem., 275, 26515, 10.1074/jbc.M003542200
Przedborski, 2000, ROS and Parkinson's disease
Przedborski, 2003, The 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine mouse model. A tool to explore the pathogenesis of Parkinson's disease, Ann. N. Y. Acad. Sci., 991, 189, 10.1111/j.1749-6632.2003.tb07476.x
Przedborski, 1992, Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity, J. Neurosci., 12, 1658, 10.1523/JNEUROSCI.12-05-01658.1992
Przedborski, 1995, Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine, Neuroscience, 67, 631, 10.1016/0306-4522(95)00066-R
Przedborski, 2001, Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease, J. Neurochem., 76, 637, 10.1046/j.1471-4159.2001.00174.x
Przedborski, 2003, Free radical and nitric oxide toxicity in Parkinson's disease
Raff, 1993, Programmed cell death and the control of cell survival, Science, 262, 695, 10.1126/science.8235590
Raff, 2002, Axonal self-destruction and neurodegeneration, Science, 296, 868, 10.1126/science.1068613
Ramsay, 1986, Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria, J. Biol. Chem., 261, 7585, 10.1016/S0021-9258(19)57434-8
Reinhard, 1987, Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells, Proc. Natl. Acad. Sci. USA, 84, 8160, 10.1073/pnas.84.22.8160
Rose, 1993, Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets, Eur. J. Pharmacol., 230, 177, 10.1016/0014-2999(93)90800-W
Saigoh, 1999, Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice, Nat. Genet., 23, 47, 10.1038/12647
Sandy, 1996, CYP2D6 allelic frequencies in young-onset Parkinson's disease, Neurology, 47, 225, 10.1212/WNL.47.1.225
Saporito, 1999, CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo, J. Pharmacol. Exp. Ther., 288, 421
Saporito, 2000, MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo, J. Neurochem., 75, 1200, 10.1046/j.1471-4159.2000.0751200.x
Satoh, 2001, A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population, J. Neurol. Sci., 189, 113, 10.1016/S0022-510X(01)00555-X
Saudou, 1998, Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions, Cell, 95, 55, 10.1016/S0092-8674(00)81782-1
Sauer, 1994, Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine, Neuroscience, 59, 401, 10.1016/0306-4522(94)90605-X
Schapira, 1990, Mitochondrial complex I deficiency in Parkinson's disease, J. Neurochem., 54, 823, 10.1111/j.1471-4159.1990.tb02325.x
Schluter, 2003, Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice, Neuroscience, 118, 985, 10.1016/S0306-4522(03)00036-8
Seniuk, 1990, Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP, Brain Res., 527, 7, 10.1016/0006-8993(90)91055-L
Sherer, 2002, An in vitro model of Parkinson's disease, J. Neurosci., 22, 7006, 10.1523/JNEUROSCI.22-16-07006.2002
Sherman, 2001, Cellular defenses against unfolded proteins, Neuron, 29, 15, 10.1016/S0896-6273(01)00177-5
Shimizu, 2001, Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat, Brain Res., 906, 135, 10.1016/S0006-8993(01)02577-X
Shimura, 2000, Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase, Nat. Genet., 25, 302, 10.1038/77060
Shimura, 2001, Ubiquitination of a new form of alpha-synuclein by parkin from human brain, Science, 293, 263, 10.1126/science.1060627
Sian, 1994, Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia, Ann. Neurol., 36, 348, 10.1002/ana.410360305
Sirinathsinghji, 1992, Cellular localization of tyrosine hydroxylase mRNA and cholecystokinin mRNA-containing cells in the ventral mesencephalon of the common marmoset, Brain Res. Mol. Brain Res., 12, 267, 10.1016/0169-328X(92)90093-Q
Snyder, 2003, Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function, J. Biol. Chem., 278, 11753, 10.1074/jbc.M208641200
Speciale, 1998, The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter, Neuroscience, 84, 1177, 10.1016/S0306-4522(97)00570-8
Sperandio, 2000, An alternative, nonapoptotic form of programmed cell death, Proc. Natl. Acad. Sci. USA, 97, 14376, 10.1073/pnas.97.26.14376
Spillantini, 1998, α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. USA, 95, 6469, 10.1073/pnas.95.11.6469
Spira, 2001, Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation, Ann. Neurol., 49, 313, 10.1002/ana.67
Staropoli, 2003, Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity, Neuron, 37, 735, 10.1016/S0896-6273(03)00084-9
Stefanis, 2001, Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death, J. Neurosci., 21, 9549, 10.1523/JNEUROSCI.21-24-09549.2001
Swerdlow, 1996, Origin and functional consequences of the complex I defect in Parkinson's disease, Ann. Neurol., 40, 663, 10.1002/ana.410400417
Takahashi, 2001, DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor, J. Biol. Chem., 276, 37556, 10.1074/jbc.M101730200
Talpade, 2000, In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone, J. Neurochem., 75, 2611, 10.1046/j.1471-4159.2000.0752611.x
Tanaka, 2001, Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis, Hum. Mol. Genet., 10, 919, 10.1093/hmg/10.9.919
Tanner, 1992, Epidemiology of Parkinson's disease, Neurol. Clin., 10, 317, 10.1016/S0733-8619(18)30212-3
Tatton, 2000, Increased Caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease, Exp. Neurol., 166, 29, 10.1006/exnr.2000.7489
Tatton, 1997, In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining, Neuroscience, 77, 1037, 10.1016/S0306-4522(96)00545-3
Thiruchelvam, 2000, Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems, Brain Res., 873, 225, 10.1016/S0006-8993(00)02496-3
Thiruchelvam, 2000, The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb, J. Neurosci., 20, 9207, 10.1523/JNEUROSCI.20-24-09207.2000
Trimmer, 1996, Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity, Neurodegeneration, 5, 233, 10.1006/neur.1996.0031
Uhl, 1994, Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons, Ann. Neurol., 35, 494, 10.1002/ana.410350421
Ungerstedt, 1968, 6-Hydroxydopamine induced degeneration of central monoamine neurons, Eur. J. Pharmacol., 5, 107, 10.1016/0014-2999(68)90164-7
Ungerstedt, 1971, Stereotaxic mapping of the monoamine pathways in the rat brain, Acta Physiol. Scand. Suppl., 367, 1, 10.1111/j.1365-201X.1971.tb10998.x
Ungerstedt, 1970, Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system, Brain Res., 24, 485, 10.1016/0006-8993(70)90187-3
Uversky, 2001, Pesticides directly accelerate the rate of alpha-synuclein fibril formation, FEBS Lett., 500, 105, 10.1016/S0014-5793(01)02597-2
van der Putten, 2000, Neuropathology in mice expressing human alpha-synuclein, J. Neurosci., 20, 6021, 10.1523/JNEUROSCI.20-16-06021.2000
Varastet, 1994, Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease, Neuroscience, 63, 47, 10.1016/0306-4522(94)90006-X
Vila, 2000, Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP, J. Neurochem., 74, 721, 10.1046/j.1471-4159.2000.740721.x
Vila, 2001, Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease, Proc. Natl. Acad. Sci. USA, 98, 2837, 10.1073/pnas.051633998
Viswanath, 2001, Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease, J. Neurosci., 21, 9519, 10.1523/JNEUROSCI.21-24-09519.2001
Volles, 2001, Vesicle permeabilization by protofibrillar alpha-synuclein, Biochemistry, 40, 7812, 10.1021/bi0102398
Wallace, 1984, Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain and heart, Life Sci., 35, 285, 10.1016/0024-3205(84)90112-7
Warrick, 1999, Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70, Nat. Genet., 23, 425, 10.1038/70532
Widdowson, 1996, Influence of age on the passage of paraquat through the blood-brain barrier in rats, Hum. Exp. Toxicol., 15, 231, 10.1177/096032719601500308
Widdowson, 1996, No changes in behaviour, nigro-striatal system neurochemistry or neuronal cell death following toxic multiple oral paraquat administration to rats, Hum. Exp. Toxicol., 15, 583, 10.1177/096032719601500706
Wilkinson, 2000, Ubiquitination and deubiquitination, Semin. Cell Dev. Biol., 11, 141, 10.1006/scdb.2000.0164
Wu, 2003, NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease, Proc. Natl. Acad. Sci. USA, 100, 6145, 10.1073/pnas.0937239100
Xia, 2001, Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease, Proc. Natl. Acad. Sci. USA, 98, 10433, 10.1073/pnas.181182298
Xu, 2002, Dopamine-dependent neurotoxicity of alpha-synuclein, Nat. Med., 8, 600, 10.1038/nm0602-600
Yang, 1998, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenauted in mice overexpressing Bcl-2, J. Neurosci., 18, 8145, 10.1523/JNEUROSCI.18-20-08145.1998
Zareparsi, 2002, Age at onset of Parkinson disease and apolipoprotein E genotypes, Am. J. Med. Genet., 107, 156, 10.1002/ajmg.10111
Zecca, 2001, Substantia nigra neuromelanin, Mol. Pathol., 54, 414